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Abstract
Obesity has become epidemic in the United States, in Europe, and in many urban areas in the developing world. The
globalization of certain ‘fast foods’ and ‘soft drinks’ may, in part, be contributing to this epidemic. Diets high in saturated
fatty acids and trans fats as well as drinks that have high fructose corn syrup levels may be particularly harmful. Recent
research suggests that fat is a dynamic endocrine organ and that visceral fat is associated with the metabolic syndrome.
Central obesity leads to organ steatosis and altered serum adipokines including reduced adiponectin and markedly elevated
leptin. This abnormal adipokine milieu results in increased tissue infiltration of monocytes and macrophages which produce
proinflammatory cytokines that alter organ function. Over many years, the combination of steatosis and local inflammation
leads to fibrosis and eventually to cancer. Nonalcoholic fatty liver disease (NAFLD) is a precursor for nonalcoholic
steatohepatitis (NASH). NAFLD and NASH (1) lead to cirrhosis and hepatocellular carcinoma, (2) increase the risk of liver
resection, and (3) compromise the outcome of liver transplantation. Similarly, in the pancreas nonalcoholic fatty pancreas
disease (NAFPD) may lead to nonalcoholic steatopancreatitis (NASP). NAFPD and NASP may (1) promote the
development of chronic pancreatitis and pancreatic cancer, (2) exacerbate the severity of acute pancreatitis, and (3) increase
the risk of pancreatic surgery. In the gallbladder nonalcoholic fatty gallbladder disease (NAFGBD, cholecystosteatosis) may
lead to steatocholecystitis. Cholecystosteatosis may be an explanation for (1) the increased incidence of chronic acalculous
cholecystitis and (2) the increased number of cholecystectomies.
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Presidential Address.
The obesity epidemic
In the USA obesity has become epidemic over the
past 15 years. Obesity is currently defined as a body
mass index (BMI) of 30. In 1990 only 1012% of
the US population had a BMI 30. However, by
1995, 1416% of Americans met this definition of
obesity. In 2000, 1820% of the US population were
obese, and in 2005 nearly 25% of Americans had a
BMI 30. The obesity problem is not confined to the
USA but is truly a global epidemic. In the Americas
outside of the USA obesity is increasing in developing
countries. In Europe, the percentage of people who
are obese varies among the many countries from 10%
to 40%. In Africa and Asia the problem of obesity is
greater in urban than in rural areas because of the
relative increased availability of food and decreased
level of activity. As in the USA and in Europe, the
problem of obesity is growing rapidly in several
countries in south-east Asia.
Diet and obesity
A key factor in the obesity epidemic is diet. Both
dietary fats and carbohydrates are likely to be playing
a role. For some time, the importance of dietary
cholesterol has been appreciated in the pathogenesis
of cardiovascular disease. As a result, the concept of
‘good’ and ‘bad’ cholesterol has emerged. Conse-
quently, high density lipoprotein (HDL) cholesterol
has been termed ‘good’ whereas low density lipopro-
tein (LDL) cholesterol has been termed ‘bad’. How-
ever, very low density lipoproteins (VLDL) also are
not good. Therefore, to fit the terminology of this talk,
cholesterol carriers can be termed ‘good’ (HDL),
‘bad’ (VLDL), and ‘ugly’ (LDL).
Similarly, fatty acids may be grouped into three
categories based on their relative value for health
(Table I). In general, polyunsaturated fatty acids
(PUFA) and omega-3 fatty acids are ‘good’. In
comparison, monounsaturated and saturated as well
as omega-6 fatty acids are ‘bad’. Even worse, trans
fatty acids, sphingolipids, and ceramides are the most
‘ugly’. Among the various oils and fats that we eat, the
relative proportion of PUFA, monounsaturated fatty
acids (MUFA), and saturated fatty acids are repre-
sented in Figure 1. At one end of the spectrum, fish
oils, which are entirely PUFA and omega-3 fatty
acids, fall in the ‘good’ category. At the other end of
the spectrum, butter fat and animal fats have the
highest percentage of saturated fatty acids and other
toxic fats which make them the most ‘ugly’.
Coincident with the obesity epidemic in the United
States and around the world has been the proliferation
of ‘fast food’ restaurants. These establishments have
been serving diets high in saturated and trans fatty
acids, ‘ugly’ fats. At the same time the per capita
consumption of ‘soft drinks’ has more than doubled in
many parts of the world. These drinks are rich in high
fructose corn syrup. Interestingly, the rise in con-
sumption of high fructose corn syrup has paralleled
the obesity epidemic (Figure 2). Unfortunately, an
unproven theory suggests that drinks with high
fructose corn syrup as the primary carbohydrate
may be another factor leading to the increased
incidence of obesity. Unfortunately, the typical fast
food diet has more than double the number of calories
(3800 versus 1800) of a ‘balanced’ diet. Moreover, a
fast food diet has twice as many carbohydrate (1900
vs 850) and fat (1500 vs 750) calories with a dramatic
increase in saturated fats. Thus, the globalization of
certain fast foods and soft drinks may, in part, be
contributing to the obesity epidemic.
Table I. Good, bad, and ugly fatty acids.
Good Bad Ugly
Polyunsaturated Monounsaturated
Saturated
Trans fatty acids
Omega-3 Omega-6 Sphingolipids
Ceramides
Fish oil Peanut oil Animal fat
Corn oil Olive Oil Butter fat
Fish Oil
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Figure 1. Fatty acids in various dietary oils and fats. PUFA,
polyunsaturated fatty acids; MUFA, monounsaturated fatty acids.
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Figure 2. Annual consumption of sugar, high fructose corn syrup,
and other sweeteners in the United States.
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Adipokines
In recent years the importance of visceral fat as an
endocrine organ which produces multiple adipokines
has been appreciated. The first adipokine to be
discovered in 1994 was leptin (Table II). A year later
adiponectin was discovered, although the importance
of this molecule as a ‘good’ factor has only been
appreciated in recent years. Resistin was first discov-
ered in 2000, and the complete role of this ‘bad’
adipokine is still being elucidated. Adiponectin is
produced by mature adipocytes, and leptin is ex-
pressed most fully by white adipocytes. In compar-
ison, in humans, resistin is produced in the bone
marrow and in monocytes. Serum levels of both
adiponectin and leptin are higher in women than in
men, whereas the reverse is true for resistin. Serum
adiponectin levels are not affected by fasting and
eating. In comparison, both resistin and leptin levels
are lower with fasting and increased after a meal.
Perhaps most importantly, adiponectin is anti-inflam-
matory whereas both resistin and leptin are proin-
flammatory.
Adiponectin has direct effects on both the vascular
endothelium and monocytes. Adiponectin down-reg-
ulates vascular adhesion molecules and, thereby,
prevents monocytes from invading tissues. In addi-
tion, adiponectin reduces the monocyte production of
the proinflammatory cytokines, tumor necrosis factor-
alpha (TNF-a) and interleukin-6 (IL-6), and in-
creases the anti-inflammatory cytokines IL-10 and
IL-1 receptor antagonist. In comparison, leptin
up-regulates vascular adhesion molecules, which leads
to monocyte and macrophage transmigration. The
macrophages produce TNF-a, IL-6, and monocyte
chemotactic protein-1 (MCP-1). In addition, TNF-a
further down-regulates adiponectin, which exacer-
bates the proinflammatory state.
The adipokines clearly play a role in the metabolic
syndrome (Table III). Patients with obesity, diabetes,
hyperlipidemia, hypertension, and cardiovascular dis-
ease all have been shown to have reduced serum
adiponectin and markedly increased leptin levels.
Similarly, resistin levels are increased in patients
who are obese, hyperlipidemic, and hypertensive,
although the data are less clear for adult onset
diabetes. Both adiponectin and leptin also have been
implicated in the pathogenesis of cancer (Table IV).
Good human data have shown that patients with
breast, endometrial, prostate, and colon cancer have
reduced adiponectin and elevated serum leptin levels.
Moreover, adiponectin decreases cell growth and
angiogenesis whereas leptin promotes these pathoge-
netic factors. In addition, leptin has been shown to
reduce immune function.
Hepatic fat
In the United States 15% of adults have nonalcoholic
fatty liver disease (NAFLD). Hepatic steatosis is
found in half of adults with diabetes, and the same
is true for patients with hyperlipidemia. In compar-
ison, 75% of patients coming to gastric bypass surgery
have NAFLD. Current thinking suggests that the
conversion from NAFLD to nonalcoholic steatohepa-
titis (NASH) requires a ‘two hit’ theory (Table V).
The first ‘hit’ is thought to be the hepatic accumula-
tion of triglycerides and increased hepatic diacylgly-
cerol. Controversy persists regarding the exact
etiology of the second ‘hit’. Multiple theories related
to altered free fatty acid metabolism, insulin resis-
tance, oxidative stress, lipid peroxidation, ceramide
accumulation, reduced adiponectin, and increased
proinflammatory cytokines have been suggested.
Nevertheless, NASH has been clearly associated
with decreased serum adiponectin (odds ratio [OR]
6.1), increased serum TNF-a (OR5.6), increased
waist-to-hip ratio (OR2.7), and increased insulin
resistance (OR1.4). In addition, 30% of patients
with NASH will develop hepatic cirrhosis over 510
years. Moreover, 10% of patients with NASH-in-
duced cirrhosis will go on to develop hepatocellular
carcinoma (HCC).
The incidence of HCC has increased in western
countries in recent years. Presently, one-third of these
western patients with HCC have no evidence of viral
hepatitis. In addition, obesity and diabetes have been
Table II. Good, bad, and ugly adipokines: adiponectin, resistin, and leptin.
Characteristic Adiponectin Resistin Leptin
Discovered 1995 2000 1994
Amino acids 247 114 167
Expression Mature adipocytes Bone marrow Monocytes White adipocytes
Females  ¡ 
Fasting  ¡ ¡
Eating   
Inflammation ¡¡  
Table III. Adipokines and the metabolic syndrome.
Parameter Adiponectin Resistin Leptin
Obesity ¡  
Diabetes ¡ ? 
Hyperlipidemia ¡  
Cardiovascular disease ¡  
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clearly demonstrated to be risk factors for HCC with
the OR for diabetes being 3.8. Thus, the combination
of hepatic steatosis and diabetes may lead to NASH
and eventually HCC. Another recently described
problem involving hepatic fat is chemotherapy-asso-
ciated steatohepatitis (CASH). Current data suggest
that irinotecan causes hepatic steatosis and that
oxaliplatin results in hepatic venous occlusion. Hepa-
tic surgery in patients with CASH is associated with
increased bleeding and infectious complications.
Moreover, a direct correlation exists between the
number of chemotherapeutic cycles and the incidence
of postoperative complications.
Presently, 20% of patients undergoing hepatic
surgery in the United States have hepatic steatosis.
These patients clearly have increased operative mor-
bidity (approximately 50%) and mortality (10%).
Patients with NAFLD undergoing hepatic resection
have increased blood loss, an increased transfusion
requirement and decreased hepatic regeneration.
Patients with NAFLD undergoing liver resection
also have been shown to have reduced hepatic
omega-3 fatty acids, reduced macro- and microcircu-
lation, and increasing necrotic cell death. Experimen-
tal data also suggest that preoperative consumption of
fish oils as well as ischemic preconditioning, which
preserves adenosine triphosphate, are protective.
NAFLD has similarly been found in 2535% of
liver donors in the United States and Europe. These
livers have diminished tolerance to both cold and
warm ischemia because of a combination of necro-
tic and apoptotic cell death, nerapotosis. Livers with
30% macrosteatosis have been shown to have poor
graft function. As a result, several investigators have
suggested that BMI, a computed tomography (CT)
fat index, or donor liver biopsies should be used to
assess hepatic steatosis. In addition, experimental data
suggest that administration of IL-6 may protect the
donor liver with steatosis.
Pancreatic fat
Similar to hepatocellular carcinoma, the association
between pancreatic cancer and obesity is robust.
Patients with pancreatic cancer are more likely to
have an elevated BMI (OR1.8) and diabetes (OR
2.0) and are less likely to be active (OR0.5) In
addition, epidemiologic data suggest that patients
with pancreatic cancer are more likely to eat a high
fat and a saturated fat diet. Moreover, pancreatic
cancer has been associated with decreased consump-
tion of PUFAs and with the intake of metformin for
adult onset diabetes. Experimental data also suggest
that PUFAs reduce and that IL-6 promotes tumor
growth.
Patients who are obese have been documented to
have more severe pancreatitis than lean individuals.
Recent experiments from our laboratory also suggest
that compared with lean mice, obese leptin-deficient
mice have more intra- and interlobular pancreatic fat
measured histologically. In addition, obese mice had
increased total fat, triglycerides, cholesterol, free fatty
acids, and saturated free fatty acids compared with
lean mice (Figure 3). In addition, obese mice had
significantly more TNF-a and IL-1b in their pan-
creas. In a follow-up study lean (C57BL/6J, leptin
normal), obese (ob/ob, leptin-deficient), and obese
(db/db, leptin-resistant) mice underwent either in-
traperitoneal saline or caerulin injections to produce
edematous pancreatitis. The obese mice had more
severe pancreatitis histologically than the lean mice,
and the hyperleptinemic obese (db/db) mice had the
most severe pancreatitis. These studies suggest that
nonalcoholic fatty pancreas disease (NAFPD) may
lead to nonalcoholic steatopancreatitis (NASP). In
addition, serum adiponectin levels correlated inver-
sely with the severity of pancreatitis, suggesting that
Table V. The ‘two hit’ theory of steatohepatitis.
First hit  hepatic triglycerides
 hepatic diacylglycerol
Second hitFree fatty acid metabolism
Insulin resistance
Oxidative stress
Lipid peroxidation
Ceramide
¡ Adiponectin
 Cytokines
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Figure 3. Pancreas concentrations of free fatty acids (FFA) (left)
and saturated FFA (right) in lean and obese mice.
Table IV. Adiponectin, leptin and cancer.
Parameter Adiponectin Leptin
Cancer types
Breast ¡ 
Endometrial ¡ 
Prostate ¡ 
Colon ¡ 
Pathogenesis
Cell growth ¡ 
Angiogenesis ¡ 
Immune function ? ¡
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low adiponectin may be more important than high
leptin levels.
Analogous to the situation with NAFLD and liver
surgery, we recently performed a clinical analysis of
NAFPD and pancreatic surgery. Forty patients who
developed a pancreatic fistula following pancreato-
duodenectomy were matched for age, gender, pan-
creatic pathology, surgeon, and type of operation with
40 control patients who did not develop a pancreatic
fistula. Patients with a pancreatic fistula had signifi-
cantly more intralobular, interlobular, and total pan-
creatic fat (Figure 4). This analysis suggests that fatty
pancreas is a risk factor for postoperative pancreatic
fistula.
Biliary fat
Similar to both hepatocellular and pancreatic cancer,
the association between gallbladder cancer and obe-
sity is well established. Both obesity and diabetes as
well as gallstones are known risk factors for gallblad-
der cancer. In addition, gallbladder cancer is signifi-
cantly more common in Pima Indians, native
Chileans, and inhabitants of northern India. All of
these populations consume high fat diets and are
prone to obesity. Obesity, diabetes, and hypertrigly-
ceridemia also are well established risk factors for
gallstones. In addition, diets high in fat, saturated fats,
cholesterol, and carbohydrates have been associated
with gallstone formation in both animals and humans.
In addition, diets high in fish oil and olive oil have
been shown to decrease the incidence of gallstones.
Moreover, statins and ezetimibe, which lower serum
and tissue cholesterol, have been shown to prevent
gallstone formation.
Recent animal data from our laboratory have
demonstrated that obese leptin-deficient (ob/ob) and
obese leptin-resistant (db/db) mice have enlarged
gallbladders that do not respond normally to neuro-
transmitters. In addition, administration of leptin
to obese ob/ob mice and ciliary neurotrophic factor
to obese db/db mice has been shown to reverse these
phenomena. Moreover, lean mice fed a high fat/high
cholesterol diet develop abnormal gallbladders that do
not empty normally, in part because of increased
cholesterol in the gallbladder wall (Figure 5). Finally,
administration of ezetimibe, which blocks fat absorp-
tion in the small intestines, lowers serum and gall-
bladder wall cholesterol, normalizes gallbladder
function, and prevents cholesterol crystal and gall-
stone formation.
A recent human study from Indiana University
confirms these murine observations. Sixteen nondi-
seased controls, 16 patients with chronic acalculous
Figure 4. Typical histologic specimen from the neck of the pancreas from a control patient (left, 5) depicting minimal pancreatic fat and
slight fibrosis and from a fistula patient (right 5) depicting significant intra- and interlobular pancreatic fat and minimal fibrosis.
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Figure 5. Cholesterol/phospholipid ratio in the gallbladder wall
of lean (C57BL/6J) and obese (ob/ob) mice on a chow (low
cholesterol) and high fat/high cholesterol (XOL) diet.
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cholecystitis, and 16 patients with calculous cholecys-
titis were matched for gender, BMI, and other
metabolic syndrome parameters. The acalculous
cholecystitis patients were significantly younger.
However, both the acalculous and calculous chole-
cystitis patients had more fat in the gallbladder
wall, cholecystosteatosis, than nondiseased controls
(Figure 6). A recent murine study comparing lean
(C57BL/6J) and obese (ob/ob) mice fed a low (45%)
and high (75%) carbohydrate diet confirmed that the
obese mice have more fat in the gallbladder and that
the high carbohydrate diet exacerbates this phenom-
enon. In addition, the obese mice and those fed a high
carbohydrate diet had increased gallbladder tissue
levels of TNF-a, IL-6, and IL-1b. These cytokines
have been associated with decreased smooth muscle
function and diminished gallbladder absorption.
Thus, the presence of increased toxic fats and proin-
flammatory cytokines, steatocholecystitis, may result
in increased gallbladder pressure and pain. As a result,
steatocholecystitis may explain the increased inci-
dence of acalculous cholecystitis and the increased
rate of cholecystectomy that has paralleled the obesity
epidemic in the United States.
Conclusions
The obesity epidemic has led to increased obesity
research. Visceral fat is now considered to be an
endocrine organ which produces multiple adipokines.
The combination of high leptin and low adiponectin is
associated with the metabolic syndrome, an insulin-
resistant state in which steatosis and proinflammatory
cytokines cause organ dysfunction. Over time and
probably with a ‘second hit’, inflammation leads to
fibrosis and, eventually, to cancer. This sequence of
events has been most clearly elucidated in the liver
where NAFLD0NASP0cirrhosis0HCC. However,
a similar process most likely occurs in the pancreas
where NAFPD0NASP0chronic pancreatitis0pan-
creatic cancer. Likewise, in the gallbladder NAFGBD
(cholecystosteatosis)0steatocholecystitis0gallstones
0gallbladder cancer. For the HPB surgeon, organ
steatosis is significant because it increases the risk of
liver resection, alters the function of the donor liver,
increases the risk of pancreatic fistula following
pancreatic resection, and increases the incidence of
chronic acalculous cholecystitis and the need for
cholecystectomy.
Figure 6. Histologic section from a nondiseased control (left), an acalculous cholecystitis patient (middle), and a calculous cholecystitis
patient (right). The cholecystitis patients had more fat in the gallbladder wall, cholecystosteatosis (alcalculous) or steatocholecystitis
(calculous).
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